• ‘No survivors’ found after explosion at Tennessee plant,…
  • Israel prepares for final hostage release as Gazans…
  • Oscar-winning actor Diane Keaton dies at 79
  • Diane Keaton, Oscar-winning actress, dies at 79

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Jimmy Kimmel's show returning tomorrow, ABC announces

admin - Latest News - September 22, 2025
admin
14 views 35 secs 0 Comments




Jimmy Kimmel’s late-night show will return to ABC’s airwaves on Tuesday, nearly a week after it was pre-empted amid criticism of the host’s remarks about the assassination of conservative activist Charlie Kirk.”Last Wednesday, we made the decision to suspend production on the show to avoid further inflaming a tense situation at an emotional moment for our country,” the Walt Disney Company said in a statement Monday.



Source link

TAGS:
PREVIOUS
Gaza protests cause disruptions across Italy
NEXT
Supreme Court takes up dispute over Trump's authority to fire FTC member
Related Post
September 24, 2025
Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleSept. 23, 2025, 10:45 PM EDTBy Abigail WilliamsThe United Nations has concluded its one-day investigation into the mysterious halting of President Donald Trump’s escalator Tuesday as he arrived at the U.N. General Assembly.The accidental culprit? A White House videographer who most likely tripped a safety mechanism.U.N. secretary general spokesperson Stéphane Dujarric said in a note to reporters that a technician found it was the White House videographer who was unintentionally behind the now-international incident that was caught on video.“The escalator had stopped after a built-in safety mechanism on the comb step was triggered at the top of the escalator,” Dujarric said. “The safety mechanism is designed to prevent people or objects accidentally being caught and stuck in or pulled into the gearing. The videographer may have inadvertently triggered the safety function described above.”But the escalator wasn’t the only thing that malfunctioned for Trump during his visit to the U.N.“I don’t mind making this speech without a teleprompter, because the teleprompter is not working,” Trump said soon after he took the podium to address all 193 delegations from around the globe.“There are two things I got from the United Nations: a bad escalator and a bad teleprompter,” he said.A U.N. official told NBC News that the White House was responsible for operating Trump’s teleprompter.The Associated Press first reported the U.N.’s findings on the two incidents.Trump appeared good-natured about all of it.“The teleprompter was broken and the escalator came to a sudden hault as we were ridding up to the podium, but both of those events probably made the speech more interesting than it would have been other wise,” Trump wrote on Truth Social. “It is always an honor to speak at the United Nations, even if, their equipment is somewhat faulty.”His press secretary, however, viewed things much differently.“If someone at the UN intentionally stopped the escalator as the President and First Lady were stepping on, they need to be fired and investigated immediately,” Karoline Leavitt wrote on X.Hours later, on Fox News, Leavitt suggested U.N. staffers may have sought to injure Trump and indicated the issue was far from resolved.”When you put all of this together, it doesn’t look like a coincidence to me,” she told host Jesse Watters.”I know that we have people, including the United States Secret Service, who are looking into this to try to get to the bottom of it,” Leavitt added. “And if we find that these were U.N. staffers who were purposely trying to trip up — literally trip up — the president and the first lady of the United States, well, there better be accountability for those people, and I will personally see to it.”Abigail WilliamsAbigail Williams is a producer and reporter for NBC News covering the State Department.Tara Prindiville contributed.
September 28, 2025
Sept. 28, 2025, 5:00 AM EDTBy Berkeley Lovelace Jr.Last winter, Brian Noonan read online that some doctors were prescribing an obscure drug, typically given to cancer patients, for autism. Curious, he looked into it for his son Benjamin, who had just been diagnosed with autism in October.“We jumped on it,” Noonan said. “It felt right and it made sense.”The medication was leucovorin, also called folinic acid. It’s a synthetic form of vitamin B9 or folate, which the body needs to make healthy blood cells. During pregnancy, folate is important to reduce the risk of birth defects.Last Monday, the drug was thrust into the national spotlight by President Donald Trump in a rambling press conference about autism that mainly focused on the president and Health Secretary Robert F. Kennedy’s claim that taking acetaminophen during pregnancy could cause autism. Trump briefly mentioned that an “existing drug” — referring to leucovorin — may help with certain symptoms of autism. For those in the autism community, leucovorin is not new. Dr. Richard Frye, a behavioral child neurologist in Phoenix has studied leucovorin and autism for two decades. He made clear that it is not a cure for autism and that more research is needed. He does, however, prescribe it to some people with autism.Noonan’s son Benjamin, who is 4 years old, is one of Frye’s patients. “He’s higher functioning,” Noonan said. “He’s verbal, but he really struggled to put together sentences.” Since starting on the medicine, the family believes Benjamin’s speech has improved, though he still has difficulties with hyperactivity and impulsiveness.Still, Noonan added, he’s under no impression that the drug is a miracle pill. Benjamin also attends a behavioral program preparing him for kindergarten, Noonan said, and he plans to enroll him in speech and occupational therapy. “We very, very much understand we’re still taking an experimental medication,” he said. The Noonan family. Benjamin, 4, who has autism, has used leucovorin.Courtesy of Brian NoonanOther families say the drug conferred larger benefits.Ben Blomgren, of Minneapolis, said his 11-year-old son, Josh, had been prescribed leucovorin off-label in February after he was at risk of being kicked out of school, even as they tried behavioral modification methods.“He’s pretty severe,” Blomgren said. “He didn’t have any language skills. He was not toilet trained.” After starting the medication, Blomgren said Josh’s sleep improved, he’s fully toilet trained and he’s stopped running away from them. “It wasn’t overnight, but we saw major improvement,” he said. Yomarie Miranda, of Florida, said she saw improvements in her 7-year-old son Ethan after he started the medication, including following instructions in class.Ethan was prescribed the medication off label earlier this month, she said.“He’s now looking at me when I speak with him. He’s talking more than before with complete sentences,” she said.A highly unusual moveThe Food and Drug Administration first approved leucovorin in the 1980s to help reduce the toxic side effects of certain chemotherapy drugs.In the decades since, researchers have also studied whether it might treat cerebral folate deficiency (CFD), a neurological condition that makes it harder for folate to reach the brain. Some children with autism also have cerebral folate deficiency, which neurologists say can affect speech, mood and behavior. Last Monday, the FDA said it planned to update the drug’s label to include that use.But the agency’s decision, experts say, rests on just a handful of small studies. And despite Trump’s endorsement, the maker of the brand-name version, GSK, has yet to submit an application to the agency to change the label. In a statement, GSK said it will be submitting the request to expand the approval to include cerebral folate deficiency, though the statement does not mention autism. (Because leucovorin is already an FDA-approved drug, doctors have been able to prescribe it “off label” for other uses, though insurance may not cover it.) It’s a highly unusual move for the FDA: pushing a drug for chemotherapy side effects as a therapy for autism without a formal submission and limited evidence.“It’s incredibly irresponsible,” said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School. “For 60-plus years, we’ve counted on the FDA to help patients distinguish between products that work and products that don’t work. And here we saw the FDA making an announcement relying on a summary of unclear data and announcing that they had already decided to approve it.”Alycia Halladay, chief science officer at the nonprofit Autism Science Foundation, was frustrated by the implication that this is a breakthrough in autism research.“It’s not like scientists have just been staring at their belly buttons for 20 years, not looking at autism treatments,” Halladay said in an interview earlier this week. “They have, but the standards have been very high to get [treatments] approved.”Andrew Nixon, a spokesperson for the Department of Health and Human Services, which oversees the FDA, said in a statement: “Analysis across 23 publications from 2009-2024 demonstrated the effectiveness for CFD. Overall, 85% of patients experienced some type of clinical benefit including improved speech/communication capabilities.” Nixon’s statement did not mention autism, and he did not respond to follow-up questions.David Mandell, a psychiatry professor at the University of Pennsylvania, said HHS’ claim that 85% of patients experienced a benefit is a “quite a conceptual leap” because it assumes people with cerebral folate deficiency also have autism.Cerebral folate deficiency “is an extremely rare event, and it is accompanied by symptoms of epilepsy, really severe neurodevelopmental problems and some of those symptoms can look like autism, but it’s not,” he said.“I could not think of a single FDA approval that has such weak evidence in the past 20 years,” Mandell added.Frye, the Phoenix neurologist, estimates up to three-quarters of autistic children have antibodies linked to cerebral folate deficiency, based on his research. Other estimates are much lower: Alycia Halladay, chief science officer at the nonprofit Autism Science Foundation, put the rates at roughly 10% to 30%.The studies on leucovorin are small but look interesting, said Dr. Scott Gottlieb, a former FDA commissioner.“It certainly merits follow up,” Gottlieb said.One of the studies was conducted by Frye: a placebo-controlled trial of more than 40 children with the antibodies, published in Molecular Psychiatry in 2018. It found around two-thirds of kids who got the drug saw improvements in verbal communication after 12 weeks. Others saw no changes. The children all had language impairments, as well as a common type of autism that’s not linked to other neurological diseases.Mandell, however, said the results shouldn’t be taken as evidence.“They claim that in certain subgroups of kids in their already small sample, they find these very large effects,” he said, adding that larger-scale trials that establish clear outcomes ahead of time are needed to verify the results. Kesselheim said it’s important for patients to have access to medications that could have a benefit, especially when there is an unmet medical need. But, he said, there are still a number of unanswered questions.“There is no accurate testing for this,” he said. “What are low folate levels? What are normal folate levels? All of that stuff should be worked out.”Frye said he currently uses two methods to assess whether a child has a folate deficiency: a spinal tap — also known as a lumbar puncture — which involves inserting a needle into the lower back to collect fluid from the spinal cord, and a folate receptor antibody test originally developed for pregnant women that isn’t approved by the FDA for diagnosing folate deficiency in children. Edward Quadros, a research professor at SUNY Downstate Health Sciences University who has worked with Frye studying leucovorin for autism, said parents are already trying the drug, including supplement versions, which aren’t regulated and can be dangerous.“By making the FDA approve it, and reputable pharmaceutical companies manufacturing it and selling it, at least it gives you quality dosing,” Quadros said.Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.Aria Bendix contributed.
October 9, 2025
Celebrations in Israel following ceasefire agreement
October 3, 2025
Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleOct. 3, 2025, 5:00 AM EDTBy Erika EdwardsMeasles outbreaks continue to simmer and spread across the country, with cases now popping up quickly in Minnesota.On Wednesday, the Minnesota Department of Health alerted residents that it had confirmed 10 new cases since Monday, bringing the state’s tally so far this year to 18.“We have been worried about this all year,” said Dr. Chase Shutak, a pediatrician and medical director at Children’s Minnesota in Minneapolis. “When the outbreaks began in Texas, all of us anticipated that it would eventually work its way up into our state.”Shutak was referring to a massive measles outbreak in West Texas, which totaled 762 cases. Ninety-nine patients needed to be hospitalized as a result of the outbreak, and two young girls died. In Minnesota, as of Thursday afternoon one child had been hospitalized at Children’s Minnesota, a spokesperson said. Most of the Minnesota cases are among families who traveled within the U.S., according to the state’s health department. None of the children had received the measles-mumps-rubella (MMR) vaccine. It was unclear, however, whether the patients were old enough to qualify for the shots, usually given in two doses starting around age 1. Arizona, too, is dealing with a large, growing outbreak that has spread across the area bordering southwestern Utah. Fifty-nine cases have been confirmed in Arizona, with one hospitalization. Most cases are in Mohave County, located in the state’s far northwestern corner, bordering Utah. “You can safely say that we are actually a part of Northern Arizona’s outbreak,” said David Heaton, public information officer for the Southwest Utah Public Health Department. “There’s one town that straddles the state line, and all of our cases appear to be linked.”Forty-four measles cases have been identified in Utah, largely among unvaccinated young people. Five needed to be admitted to the hospital but have since recovered, Heaton said.If outbreaks continue around the country until the end of January, the United States will lose its status of having had eliminated measles 25 years ago. This week, the Centers for Disease Control and Prevention reported a total of 1,544 confirmed measles cases. Of those, just 21 cases were diagnosed in people visiting the U.S. from other countries. The government shutdown hasn’t affected the CDC’s monitoring of the ongoing measles spread, according to a person in leadership who was not authorized to speak to the media.Falling vaccination ratesA recent NBC News investigation found notable declines in childhood vaccination rates in more than three-quarters of counties and jurisdictions since 2019. And among states with data on kids who get the MMR vaccine, 67% don’t have enough coverage for herd immunity.
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved